002155:SZSEHunan Gold Corporation Limited Analysis
Data as of 2026-06-17 - not real-time
CN¥26.29
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Hunan Gold is trading above its fair‑value estimate, with price comfortably above the discounted cash‑flow target and a price‑to‑book multiple that suggests premium valuation. The stock shows a neutral technical stance: the MACD histogram is positive, indicating recent bullish momentum, while the RSI hovers around the midpoint, implying no extreme overbought or oversold condition. Volume is rising, supporting the price action as it approaches a near‑term resistance zone.
Fundamentally, the company delivers robust revenue growth and strong cash generation, paired with negligible debt and a modest dividend payout that appears sustainable. However, margins remain thin, and the valuation premium may limit upside unless commodity fundamentals improve or the market re‑prices the growth narrative.
Fundamentally, the company delivers robust revenue growth and strong cash generation, paired with negligible debt and a modest dividend payout that appears sustainable. However, margins remain thin, and the valuation premium may limit upside unless commodity fundamentals improve or the market re‑prices the growth narrative.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Positive MACD histogram indicating short‑term bullish pressure
- Price nearing a near‑term resistance level
- Elevated volatility that could prompt sharper moves
Medium Term
1–3 yearsNeutral
Model confidence: 7/10
Key Factors
- Strong top‑line growth and ample cash flow generation
- Very low leverage and a low dividend payout ratio
- Valuation still above intrinsic estimate, limiting upside
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- Sustained demand for gold and related metals supporting earnings
- Solid balance sheet with negligible debt and consistent dividend
- Potential for price re‑rating if commodity fundamentals improve
Key Metrics & Analysis
Financial Health
Revenue Growth43.50%
Profit Margin3.13%
P/E Ratio23.5
ROE22.17%
ROA14.33%
Debt/Equity0.03
P/B Ratio4.7
Op. Cash FlowCN¥1.5B
Free Cash FlowCN¥756.6M
Technical Analysis
TrendNeutral
RSI53.2
SupportCN¥22.50
ResistanceCN¥26.97
MA 20CN¥24.79
MA 50CN¥27.46
MA 200CN¥25.63
MACDBullish
VolumeIncreasing
Fear & Greed Index92.13
Valuation
Fair ValueCN¥18.86
Target PriceCN¥27.32
Upside/Downside3.92%
GradeOvervalued
TypeGrowth
Dividend Yield1.13%
Risk Assessment
Beta0.12
Volatility46.58%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.